List of Excipients in Branded Drug FEXOFENADINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NCS HealthCare of KY Inc dba Vangard Labs	FEXOFENADINE HYDROCHLORIDE	fexofenadine hydrochloride	0615-5620	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	FEXOFENADINE HYDROCHLORIDE	fexofenadine hydrochloride	0615-5620	CROSCARMELLOSE SODIUM
NCS HealthCare of KY Inc dba Vangard Labs	FEXOFENADINE HYDROCHLORIDE	fexofenadine hydrochloride	0615-5620	FERROUS OXIDE

Generic Drugs Containing FEXOFENADINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Walgreen CO	fexofenadine hydrochloride	0363-0097	ANHYDROUS LACTOSE
Walgreen CO	fexofenadine hydrochloride	0363-0097	CROSCARMELLOSE SODIUM
Walgreen CO	fexofenadine hydrochloride	0363-0097	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in FEXOFENADINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	AMMONIA
37	ANHYDROUS LACTOSE
3	BUTYLATED HYDROXYANISOLE

Fexofenadine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Fexofenadine hydrochloride is a mature, largely commoditized antihistamine with limited conventional patent protection and broad over-the-counter availability. Commercial differentiation depends on excipient-enabled performance: rapid disintegration, taste masking, pediatric acceptability, low-moisture stability, liquid-dose convenience, and combination-product design. The strongest opportunities are orally disintegrating tablets, pediatric liquids, chewables, orally dissolving films, and differentiated combination products rather than standard immediate-release tablets.

What is the commercial position of fexofenadine hydrochloride?

Fexofenadine hydrochloride is a second-generation H1 antihistamine used for seasonal allergic rhinitis and chronic idiopathic urticaria. It is the active metabolite of terfenadine and has low central nervous system penetration relative to first-generation antihistamines. U.S. products include tablets, orally disintegrating tablets, oral suspension, and combination products with pseudoephedrine.

The product is mature in the United States and many international markets. The original prescription-to-OTC transition occurred in the 1990s, and fexofenadine is now sold through branded, store-brand, generic, and private-label channels. The basic 30 mg, 60 mg, 120 mg, and 180 mg immediate-release tablet markets have limited formulation differentiation.

Commercial attribute	Fexofenadine hydrochloride position
Therapeutic class	Second-generation H1 antihistamine
Primary indications	Allergic rhinitis; chronic idiopathic urticaria
Common adult strengths	60 mg, 120 mg, 180 mg
Pediatric strength	30 mg commonly used in children
Major dosage forms	Tablets, orally disintegrating tablets, oral suspension, combination tablets
Regulatory status	FDA-approved prescription and OTC products; generic availability
Primary commercial constraint	Price competition in standard tablets
Best differentiation route	Taste, convenience, fast dissolution, pediatric dosing, combination products
Principal patent risk	Low for ordinary immediate-release fexofenadine products
Main technical risks	Taste, powder flow, dissolution, moisture sensitivity, dose uniformity, excipient acceptability

The commercial ceiling for a new standard tablet is low unless the product has a meaningful distribution advantage, a private-label customer, or a lower-cost manufacturing platform.

What excipients are used in fexofenadine hydrochloride products?

Approved formulations use conventional tablet and liquid excipients, but the specific qualitative and quantitative composition differs by manufacturer and dosage form. FDA labeling and DailyMed records should control the final product-specific assessment because inactive ingredients can vary across National Drug Code products.[1,2]

Immediate-release tablets

Typical excipient functions include:

Function	Candidate excipients
Diluent and compression aid	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate, sodium stearyl fumarate
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, talc, iron oxides
Sweetener or flavor	Sucralose, aspartame, acesulfame potassium, flavor systems
Moisture-control system	Desiccant packaging, high-barrier blister, low-water-activity excipients

The core formulation objective is rapid tablet breakup without excessive friability. Fexofenadine hydrochloride tablets must also meet dissolution and assay uniformity requirements across commercial-scale compression.

Orally disintegrating tablets

ODT systems require a different excipient strategy. The formulation must disintegrate quickly in the mouth while maintaining adequate mechanical strength during packaging, shipping, and consumer handling.

Common ODT excipients include:

• Mannitol for mouthfeel and cooling sensation.
• Crospovidone or croscarmellose sodium for rapid wicking.
• Low-substituted hydroxypropyl cellulose for disintegration and tablet strength.
• Microcrystalline cellulose or silicified microcrystalline cellulose for compactability.
• Aspartame, sucralose, or acesulfame potassium for sweetness.
• Flavor systems to reduce the active ingredient's bitterness.
• Magnesium stearate or sodium stearyl fumarate at controlled concentrations.

Mannitol-based direct compression is commercially attractive because it creates a smooth mouthfeel and can support low tablet weights. The formulation risk is that high mannitol loading can reduce compactability or increase tablet friability. Excessive hydrophobic lubricant can slow wetting and dissolution.

Oral suspension

Liquid fexofenadine products are relevant to pediatric and swallowing-impaired populations. A suspension strategy generally requires:

• Suspending polymer, such as xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose and carboxymethylcellulose sodium, or hypromellose.
• Wetting agent, where needed.
• Buffer system to control pH.
• Preservative, such as sodium benzoate or potassium sorbate, subject to product-specific compatibility.
• Sweetener and flavor.
• Chelating agent, if justified by stability data.
• Antifoam or processing aid, where required.

The liquid must provide uniform dose delivery after shaking, acceptable sedimentation behavior, rapid redispersion, preservative effectiveness, and chemical stability. Pediatric products also face scrutiny over sugar content, alcohol, propylene glycol, sodium, allergen declarations, and artificial colors.

What formulation problems are most important for fexofenadine hydrochloride?

How should fexofenadine taste be masked?

Taste is the main excipient-driven barrier for pediatric and orally disintegrating products. A simple sweetness increase may not adequately address the active ingredient's bitterness or lingering aftertaste. A more effective system can combine:

1. High-intensity sweetener.
2. Fruit or citrus flavor.
3. Bitter-blocking or taste-modifying technology.
4. Polymer coating or ion-exchange resin complexation.
5. Rapid swallow profile that limits residence time in the mouth.

Taste masking must not reduce dissolution after swallowing. Coated particles can create a dissolution delay, especially if the coating polymer is too hydrophobic or too thick. Ion-exchange resin systems can improve palatability but add processing steps, regulatory justification, and release testing.

A commercially credible taste-masked formulation should compare sensory performance against an approved or leading OTC product, not only against unformulated fexofenadine hydrochloride.

How can excipients improve dissolution?

Fexofenadine hydrochloride is a salt form, but dissolution performance still depends on particle size, wetting, tablet porosity, compression force, and lubricant level. Practical approaches include:

• Particle-size control of the active ingredient.
• Crospovidone or croscarmellose sodium for capillary-driven breakup.
• Surfactant-assisted wetting at low concentrations.
• Porous mannitol or silicified microcrystalline cellulose.
• Granulation control to prevent dense, slow-wetting granules.
• Reduced magnesium stearate blending time.
• Disintegrant placement in both intra- and extragranular phases.

A formulation patent based only on routine excipient substitution is vulnerable to obviousness challenges. Stronger protection requires a defined composition range linked to an unexpected result, such as rapid dissolution under robust test conditions, superior stability, reduced aftertaste, or improved dose uniformity.

How should moisture and packaging be managed?

Moisture can affect powder flow, tablet hardness, disintegration, coating performance, and preservative stability. ODTs and chewables are especially sensitive because they often use highly soluble or hygroscopic excipients.

Commercial options include:

• Aluminum-aluminum blisters.
• High-barrier cold-form or thermoform blister systems.
• Desiccant bottles.
• Low-moisture direct-compression excipients.
• Water-activity specifications for granules and finished tablets.
• Moisture-resistant film coating.

Packaging can provide a practical differentiation point without creating a drug patent. It may also support premium pricing in travel, pediatric, and unit-dose channels.

What excipient strategies offer the best commercial opportunities?

Product concept	Commercial rationale	Excipient focus	Development value
Low-weight ODT	Convenience and no-water administration	Mannitol, crospovidone, sweeteners, flavors	High
Pediatric ODT or chewable	Better adherence and improved acceptability	Taste masking, mannitol, resin complex, sweeteners	High
Ready-to-use suspension	Pediatric and geriatric dosing	Suspending polymer, preservative, flavor, buffer	High
Oral dissolving film	Portable and discreet dosing	Film former, plasticizer, saliva-triggered disintegration	Medium to high
Extended-release combination product	Differentiation from basic antihistamine tablets	Matrix former, release-controlling polymer	Medium
Fexofenadine plus pseudoephedrine	Decongestant market and seasonal allergy use	Bilayer or multilayer tablet, release separation	Medium
Chewable tablet	Consumer convenience	Compressible mannitol, flavor, sweetener, taste masking	Medium
Standard 180 mg tablet	Broad market but low differentiation	Low-cost direct compression	Low

The highest-value opportunity is a pediatric-friendly product that combines reliable taste masking, fast oral disintegration, and simple dosing. A 30 mg ODT, chewable, or low-viscosity suspension can compete through patient experience rather than active-ingredient novelty.

What patents protect fexofenadine hydrochloride formulations?

The original fexofenadine and terfenadine-related patent families are historical assets. Core composition and use patents have generally reached the end of their ordinary U.S. patent terms, and generic fexofenadine products have been marketed for years. The relevant commercial question is therefore whether a specific new formulation, combination, manufacturing process, or delivery system has a later patent.

Potential patent categories include:

Patent category	Relevance to fexofenadine	Current strategic value
Active compound patents	Historical protection for fexofenadine-related chemistry	Low for new entry
Salt and polymorph patents	Could address crystalline form or solid-state properties	Product-specific
Immediate-release composition patents	May claim excipient ranges or dissolution performance	Usually narrow
ODT patents	Could claim taste masking, tablet structure, or disintegration	Meaningful if technically differentiated
Liquid formulation patents	Could cover suspension stability, viscosity, or preservative systems	Meaningful for pediatric products
Combination patents	Could cover fexofenadine and pseudoephedrine arrangements	Relevant to combination products
Method-of-use patents	Could claim dosing or patient populations	Usually limited in OTC competition
Manufacturing patents	Could cover granulation, particle engineering, or coating	Relevant where process controls are difficult
Packaging patents	Could cover moisture protection or unit-dose delivery	Usually secondary

The Orange Book should be reviewed for each branded and prescription-listed product before launch planning. Patent listings are product-specific and can differ by dosage form, strength, and indication. FDA's Orange Book records therapeutic equivalence, approved applications, patent listings, and exclusivity information.[3]

How strong is the patent estate for a new fexofenadine formulation?

A new fexofenadine formulation has moderate patent potential only if it solves a measurable technical problem. Stronger claims could cover:

• A defined taste-masked particle architecture.
• A narrow excipient ratio that produces rapid disintegration and acceptable hardness.
• A suspension with specified sedimentation, redispersibility, and preservative performance.
• A multiparticulate product with controlled release and demonstrated pharmacokinetic benefit.
• A combination product with separated release profiles.
• A manufacturing process that produces consistent particle coating or content uniformity.

Weak claims would cover broad lists of conventional excipients without a demonstrated technical effect. Patent applicants should generate comparative data against multiple conventional formulations. Dissolution, disintegration, friability, taste, stability, and pharmacokinetic data can help establish non-obviousness.

When does fexofenadine lose exclusivity?

Fexofenadine's basic U.S. market exclusivity has already elapsed. The product has generic and OTC competition, and standard immediate-release tablets do not depend on a current molecule-level exclusivity period.

Exclusivity layer	Status
New chemical entity exclusivity	Expired
Original composition patents	Expired or commercially exhausted
Basic immediate-release generic entry	Established
Pediatric exclusivity	Historical, expired
New formulation exclusivity	Depends on future FDA approval
New combination exclusivity	Depends on product-specific approval and patent status
OTC monograph pathway	Product-specific; depends on applicable FDA requirements

A later formulation could qualify for regulatory exclusivity only if it meets the applicable statutory requirements. A reformulated product does not automatically obtain meaningful exclusivity. FDA approval, labeling, clinical evidence, and the nature of the innovation determine whether any additional exclusivity is available.[4]

Are Paragraph IV challenges relevant to fexofenadine?

Paragraph IV risk is low for the ordinary generic fexofenadine market because the key original patents are old and generic products are established. Paragraph IV activity could still arise for:

• A newly approved ODT.
• A long-acting formulation.
• A protected taste-masking system.
• A new fexofenadine-pseudoephedrine dosage form.
• A later-listed method-of-use or formulation patent.

For a new branded formulation, the risk analysis should distinguish between patent validity, infringement, and commercial enforceability. A patent listed in the Orange Book can trigger a 30-month stay following a Paragraph IV certification if statutory requirements are met. That mechanism is relevant to new listed products, not to the expired core fexofenadine molecule.[5]

What FDA regulatory pathway applies to fexofenadine products?

ANDA pathway

A conventional generic tablet can generally use the ANDA pathway if it matches the reference product in active ingredient, dosage form, strength, route, and applicable performance requirements. Bioequivalence, dissolution, manufacturing controls, labeling, and inactive-ingredient acceptability remain central.

OTC pathway

An OTC product may proceed under an applicable monograph or through an approved NDA, depending on the dosage form and regulatory framework. OTC switches and branded OTC products can involve different evidence and labeling requirements. Fexofenadine products must comply with active-ingredient, dosage, labeling, and manufacturing requirements applicable to the selected pathway.

505(b)(2) pathway

A differentiated suspension, ODT, film, combination product, or modified-release product may be suitable for a 505(b)(2) application when the applicant relies partly on existing FDA findings but introduces a clinically or technically distinct product. The pathway can be useful when the new formulation has different excipients, dosing convenience, delivery characteristics, or labeling.

FDA's inactive ingredient database can support excipient selection, but prior use in an approved product does not eliminate the need for formulation-specific safety, compatibility, stability, and quality evaluation.[6]

Which companies are challenging or competing with fexofenadine products?

Competition is fragmented across branded consumer-health companies, generic manufacturers, retail chains, and private-label distributors. Historical branded competition includes loratadine, cetirizine, levocetirizine, desloratadine, and their combination products. Fexofenadine's principal competitive advantages are low sedation perception, established consumer recognition, and multiple dosage strengths.

Competitor class	Representative products	Competitive pressure
Fexofenadine brands	Allegra and regional equivalents	Brand recognition and advertising
Store brands	Retailer-labeled fexofenadine	Price pressure
Generic manufacturers	Multiple ANDA holders	Lowest-cost tablet supply
Loratadine products	Claritin and generics	Similar once-daily positioning
Cetirizine products	Zyrtec and generics	Strong allergy-channel presence
Combination products	Antihistamine plus pseudoephedrine	Decongestant convenience
Novel delivery suppliers	ODT, chewable, liquid, film developers	Formulation differentiation

Private-label buyers may favor suppliers that can offer reliable seasonal capacity, low minimum order quantities, dual sourcing, and differentiated dosage forms.

What licensing deals and manufacturing barriers matter?

No active ingredient license is generally required to commercialize ordinary fexofenadine hydrochloride generic products. Licensing may become relevant for:

• Taste-masking technology.
• Ion-exchange resin complexes.
• Multiparticulate coating systems.
• Oral film platforms.
• Proprietary direct-compression excipients.
• Pediatric flavor systems.
• High-barrier packaging.
• Contract manufacturing capacity for seasonal demand.

Manufacturing barriers are operational rather than molecule-specific. They include active-ingredient particle-size variability, blend segregation, content uniformity at low dose, tablet capping, ODT friability, suspension redispersibility, and seasonal demand concentration.

A supplier with validated taste-masking equipment, low-shear coating capability, and pediatric liquid experience can command more value than a tablet-only manufacturer. Dual sourcing is important because allergy-product demand is seasonal and supply interruptions can affect retail placement.

What generic launch scenarios exist?

Low-cost standard tablet launch

This is the fastest route but has the weakest margin profile. Success depends on procurement, scale, retailer access, and supply reliability. Patent barriers are limited.

Premium ODT or chewable launch

This route supports stronger differentiation and may use a 505(b)(2) or OTC strategy depending on the product. The main risks are taste, mechanical strength, stability, and consumer acceptance.

Pediatric suspension launch

This route has a clear patient-use rationale. The commercial case improves if the product provides a measuring device, low sugar, acceptable flavor, and robust shelf stability.

Combination-product launch

Fexofenadine-pseudoephedrine products can capture seasonal congestion demand. The formulation must manage different release requirements and regulatory controls for pseudoephedrine, including applicable sales restrictions and supply-chain monitoring.

Private-label platform launch

A manufacturer can use one excipient platform across multiple strengths and retail customers. This reduces development costs and supports rapid customer-specific packaging changes.

What is the revenue exposure for fexofenadine products?

Revenue exposure is highest in the spring and summer allergy seasons and in regions with persistent allergic rhinitis. Standard tablets face substantial price erosion, while revenue per unit can be higher for ODTs, liquids, chewables, films, and combination products.

The strongest commercial model is often a portfolio rather than a single SKU:

• 30 mg pediatric product.
• 60 mg twice-daily or 120 mg once-daily adult product.
• 180 mg once-daily adult product.
• ODT or chewable line extension.
• Oral suspension.
• Combination product where permitted.
• Retailer-specific private-label packaging.

A differentiated excipient platform can improve gross margin by reducing returns, improving consumer acceptance, and supporting premium positioning. It does not by itself create durable market exclusivity.

Key Takeaways

• Fexofenadine hydrochloride is a mature active ingredient with established generic and OTC competition.
• Standard immediate-release tablets offer limited commercial differentiation and low patent value.
• Taste masking, ODT performance, pediatric dosing, and liquid stability are the strongest excipient-led opportunities.
• Mannitol, crospovidone, croscarmellose sodium, polymeric binders, sweeteners, flavors, and moisture-protective packaging form the core development toolkit.
• New patent value depends on narrow formulation architecture, comparative data, and a demonstrated technical effect.
• Paragraph IV risk is limited for the core molecule but can become relevant for later-listed ODT, liquid, combination, or modified-release patents.
• A 505(b)(2) strategy may be appropriate for a clinically or technically differentiated dosage form.
• Commercial success depends more on retail access, seasonal supply, taste, packaging, and manufacturing consistency than on molecule-level exclusivity.
• The most attractive platforms are pediatric ODTs, chewables, oral suspensions, and premium private-label products.

FAQs About Fexofenadine Hydrochloride Excipient Strategy

Can fexofenadine hydrochloride be formulated as an orally disintegrating tablet?

Yes. An ODT can use mannitol, crospovidone or croscarmellose sodium, sweeteners, flavors, and controlled lubricant levels. The critical performance requirements are rapid disintegration, acceptable mouthfeel, low friability, and adequate post-swallow dissolution.

Which excipients are best for masking fexofenadine bitterness?

A combined system using mannitol, high-intensity sweetener, flavor, and either coated particles or an ion-exchange resin complex is more robust than sweetness alone. The selected system must preserve dissolution and stability.

Is a new fexofenadine formulation patentable?

It can be, but routine substitution of commonly used excipients is unlikely to produce strong protection. Patentability improves when the formulation has a defined structure, narrow composition range, manufacturing limitation, and comparative technical benefit.

Does fexofenadine require biosimilar analysis?

No. Fexofenadine hydrochloride is a small-molecule drug, not a biologic. Biosimilar requirements do not apply. Generic, NDA, ANDA, OTC, or 505(b)(2) frameworks are the relevant pathways.

Can a company obtain exclusivity for a new fexofenadine liquid or ODT?

Potentially, but exclusivity depends on the regulatory pathway, product innovation, clinical evidence, and patent strategy. A new dosage form does not automatically receive meaningful market exclusivity.

References

1. U.S. Food and Drug Administration. (2024). Fexofenadine hydrochloride product labeling and inactive ingredients. DailyMed.

2. National Library of Medicine. (2024). DailyMed: Fexofenadine hydrochloride tablets, orally disintegrating tablets, and oral suspension labels. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Small business and industry assistance: Drug development and approval pathways. FDA.

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.

6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.